Ronny Gal, a biopharmaceutical analyst with Bernstein, suggested in a recent report that overall prices for cancer treatments “are likely to decline by 70% in five years” as biosimilar competition enters the fold, according to a Regulatory Affairs Professionals Society report.
Amgen and Allergan are preparing to launch biosimilars with list prices 15 percent lower than their reference drugs, according to the report.
“Hypothetically, price can go down 90%+ given the higher starting point of US prices,” Gal, referencing the upcoming Kanjinti biosimilar, wrote. “With five competitors, market price could crash, but the companies involved in the first wave are all pretty sophisticated and the buyers are fragmented.”
To read more on RAPS, click here.